Valuation: Assembly Biosciences, Inc.

Market Cap 492M 432M 402M 370M 694M 47.03B 705M 4.77B 1.87B 23.32B 1.85B 1.81B 80.58B P/E 2026 *
-23.6x
P/E 2027 * -8.92x
Enterprise Value 492M 432M 402M 370M 694M 47.03B 705M 4.77B 1.87B 23.32B 1.85B 1.81B 80.58B EV / Sales 2026 *
10.8x
EV / Sales 2027 * 15.3x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day-1.31%
1 week-3.40%
Current month-6.95%
1 month-4.38%
3 months-5.30%
6 months-3.22%
Current year-24.82%
1 week 24.85
Extreme 24.85
26.56
1 month 24.85
Extreme 24.85
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
6/17/26 A Sell

Chief Financial Officer

-29 0.0002%
6/4/26 A Free

Chairman

8,000 0.0514%
6/4/26 A Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
-1.31%-3.40%+31.13%+90.25% 499M
+0.14%-0.67%-0.88%+11.02% 47.74B
-2.24%+0.31%+393.45%+615.13% 39.98B
+1.40%+3.69%+12.21%+46.79% 36.23B
+13.94%+20.49%+22.85%+7.42% 35.59B
-0.73%+3.38%+4.94%+41.45% 27.91B
+0.40%-0.30% - - 16.71B
-3.12%+7.39%+26.03%+124.08% 16.45B
+2.39%-1.64%+4.74%+9.95% 13.21B
+6.79%+8.17%-4.97%-28.52% 12.93B
Average +1.77%+3.01%+54.39%+101.95% 24.73B
Weighted average by Cap. +2.09%+2.54%+76.01%+130.50%

Financials

2026 *2027 *
Net sales 45.47M 39.9M 37.16M 34.18M 64.07M 4.34B 65.17M 441M 173M 2.15B 171M 167M 7.44B 32.25M 28.3M 26.36M 24.24M 45.44M 3.08B 46.22M 313M 122M 1.53B 121M 118M 5.28B
Net income -20.46M -17.96M -16.72M -15.38M -28.83M -1.95B -29.33M -198M -77.66M -970M -76.82M -75.16M -3.35B -56.38M -49.48M -46.07M -42.38M -79.44M -5.39B -80.8M -547M -214M -2.67B -212M -207M -9.23B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
28/07/26 $25.57 -1.31% 86,407
27/07/26 $25.91 +1.41% 79,179
24/07/26 $25.55 +1.31% 142,149
23/07/26 $25.22 -3.15% 191,256
22/07/26 $26.04 -1.62% 128,331
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
25.57USD
Average target price
50.00USD
Spread / Average Target
+95.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock